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Summary
Context The short ACTH stimulation test (250 lg) is the
dynamic test most frequently used to assess adrenal function. It
is possible that a single basal cortisol could be used to predict
the dynamic response, but research has been hampered by the
use of different assays and thresholds.
Objective To propose a morning baseline cortisol criterion of
three of the most commonly used modern cortisol immunoas-
says – Advia Centaur (Siemens), Architect (Abbott) and the
Roche Modular System (Roche) – that could predict adrenal
sufficiency.
Design Observational, retrospective cross-sectional study at two
centres.
Patients and Measurements Retrospective analysis of the
results of 1019 Short Synacthen tests (SSTs) with the Advia Cen-
taur, 449 SSTs with the Architect and 2050 SSTs with the Roche
Modular System assay. Serum cortisol levels were measured prior
to injection of 250 lg Synacthen and after 30 min. Overall, we
were able to collate data from a total of 3518 SSTs in 3571
patients.
Results Using receiver–operator curve analysis, baseline cortisol
levels for predicting passing the SST with 100% specificity were
358 nmol/l for Siemens, 336 nmol/l for Abbott and 506 nmol/l
for Roche. Utilizing these criteria, 589, 158 and 578 SSTs, respec-
tively, for Siemens, Abbott and Roche immunoassays could have
been avoided.
Conclusions We have defined assay-specific morning cortisol
levels that are able to predict the integrity of the hypothalamo–
pituitary–adrenal axis. We propose that this represents a valid
tool for the initial assessment of adrenal function and has the
potential to obviate the need for dynamic testing in a significant
number of patients.
(Received 14 June 2016; returned for revision 16 August 2016;
finally revised 16 August 2016; accepted 7 September 2016)
Introduction
Careful evaluation of adrenal function is essential in patients
with disease that can affect the hypothalamo–pituitary–adrenal
(HPA) axis. Laboratory evaluation is recommended in patients
suspected to have primary adrenal insufficiency (AI) and in
those at risk of developing AI following prolonged glucocorti-
coid (GC) therapy, hypothalamo–pituitary disease and related
surgery or radiation, and in patients with other proven disorders
of the HPA axis.
The established ‘gold standard’ test for the assessment of the
HPA axis is to measure the cortisol response to insulin-induced
hypoglycaemia.1–4 However, while in extensive use and with a
good safety record, this test remains potentially dangerous for
the patient and is highly demanding in terms of the experienced
medical supervision required.5 It is contraindicated in patients
with cerebrovascular diseases, epilepsy, ischaemic heart disease
and severe metabolic disorders and is not recommended in
young children or patients with concomitant serious disease.6,7
Stimulation of the adrenal with exogenous ACTH (Synacthen,
Cosyntropin) at the conventional dose of 250 lg of Synacthen
has been described as a reliable screening method in patients
with suspected adrenal impairment due to hypothalamic or pitu-
itary dysfunction and has been validated against insulin-induced
hypoglycaemia (ITT).5,8–18 In general, other than in patients
with an acute insult to the HPA axis as immediately after pitu-
itary surgery,19–21 this test has been shown to correlate well with
more complex testing procedures, is rapid and simple to per-
form and has been claimed in extensive use to show an absence
of severe side effects or contraindications.
However, the SST is associated with a small risk of hypersen-
sitivity reactions and with the need for medical observation fol-
lowing the administration of Synacthen: the Society for
Endocrinology has recommended that it only be performed in
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units where immediate resuscitation facilities are available. As an
alternative, random serum cortisol measurements are considered
to be unreliable as there is a diurnal rhythm of cortisol secretion
and low levels may simply be a physiological response to circa-
dian rhythmicity. However, such a rhythm peaks at around
0800–0900 h, and previous authors have demonstrated the
presence of a strong correlation between such basal morning
(0800–0900 h) serum cortisol and maximal-stimulated cortisol
levels during the ITT22 and also between basal cortisol levels and
peak levels following ACTH administration.8,23 Thus, in previous
studies, with a basal morning cortisol of less than 100 nmol/l or
more than 500 nmol/l the SST was of little added value.24
Nevertheless, in other studies, basal cortisol measurements in
the range 300–500 nmol/l have been suggested as rendering full
stimulation with ACTH unnecessary.19,22,25,26 Unfortunately,
many of these studies are hampered by the use of differing
assays and thus varying thresholds for defining a normal
response, with criteria for one assay used to define normality in
a different assay. This variation between assays is critical and
was emphasized in a recent study of a comparison of the nor-
mative responses to Synacthen using a variety of different corti-
sol measurements.27
In a previous study, the data from a single centre were anal-
ysed using a single assay. We have now conducted a retrospec-
tive study analysing SSTs performed at two major centres, the
Oxford Centre for Diabetes, Endocrinology and Metabolism
(OCDEM) in Oxford, UK, between January 2011 and April 2016
and at the Centre for Endocrinology, Diabetes and Metabolism
at the University Hospital of Birmingham, UK, between January
2008 and December 2012, to assess the predictive value of base-
line morning serum cortisol in determining the outcome of SST
to evaluate adrenal reserve using a variety of different assays,
and looking at the effect of the timing of the sampling. Data
from the cohort of patients undergoing SST analysed by the
Roche assay have been presented previously.23 In this article, a
discrete subset of this cohort was analysed where specific indica-
tions for performing the SST were documented paralleling the
clinical data in patient samples analysed by the Centaur and
Architect assays. We therefore have attempted to broaden the use
of single morning cortisol samples and provide normative values
which can be more generally applicable to different centres.
Methods
Study population and assays
This study was an observational, retrospective cross-sectional
analysis of all SSTs performed in two secondary/tertiary care
centres across all medical specialities with three different
cortisol assays: Siemens Advia Centaur immunoassay analyser
(Siemens Healthcare Diagnostics, Frimley, UK), Abbott
Architect i-2000 immunoassay analyser (Abbott Diagnostics,
Maidenhead, UK) and the Roche Modular System (Roche,
Mannheim, Germany).
Overall, we were able to collate data from a total of 3957
outpatient SSTs in 3571 patients. We collected and analysed
the results of 1375 SSTs performed in 1050 patients at
OCDEM, Oxford University Hospitals NHS Foundation Trust,
UK, between January 2011 and December 2014 when cortisol
samples were analysed with Advia Centaur, the results of 532
SSTs performed in 471 patients at OCDEM, Oxford
University Hospitals NHS Foundation Trust, UK between
January 2015 and April 2016 when cortisol samples were
analysed with Architect and the results of SSTs performed in
2050 patients at the Queen Elizabeth Hospital, University
Hospitals Birmingham NHS Foundation Trust, UK, between
January 2008 and December 2012 with the Roche Modular
System.
All results were collected from the electronic medical record
system. The indication for the SST was derived from clinical
fields and clinical letters to general practitioners. We excluded
SSTs performed without any clear indication or with a non-
specified indication; thus, we were able to analyse the results
of 1019 SSTs performed with Advia Centaur, 449 with
Architect and 2050 with Roche Modular system, a total of
3518.
All SSTs were performed in the morning (0830 h–1200 h),
but for the data from Oxford (Advia Centaur and Architect) only
those tests started in the time range 0830–1000 h were
included in the principal analysis. However, we performed a sec-
ondary analysis including only SSTs initiated after 1000 h com-
prising 443 SSTs analysed by Advia Centaur and 109 SSTs
analysed by Architect (we did not analyse the latter data due to
the small sample size).
With regard to the Roche Modular System data, all SSTs were
initiated between 0830 h and 1200 h, but the exact time of the
beginning of the test was not recorded, and thus, we were
unable to perform a secondary analysis based on the precise
time of beginning of the test in this cohort.
Patients on the oral contraceptive pill or other oestrogen
replacement were required to stop the treatment at least 6 weeks
before the test. Baseline serum cortisol levels were measured prior
to injection of 250 lg Synacthen (Synacthen 250 lg, Questcor
Operations Limited, Dublin, Ireland) for the groups of Siemens
and Abbott assays and 250 lg Synacthen (Alliance Pharmaceuti-
cals, Chippenham, UK) for the group of Roche assays, intramus-
cularly; for the Abbott assay Synacthen was injected
intramuscularly until December 2015 and then, from January to
April 2016, intravenously. Blood was sampled for serum cortisol
at baseline and after 30 min. The 30 min response to intramuscu-
lar or intravenous Synacthen has been shown to be equivalent.28
After administration of Synacthen, the patients were observed for
15 min for signs of any allergic reaction.
Serum cortisol analysed by Advia Centaur showed an interas-
say imprecision of 105% at 83 nmol/l, 60% at 524 nmol/l and
70% at 904 nmol/l; by Architect of 56% at 72 nmol/l, 22% at
433 mol/l and 24 at 667 mol/l; and by the Roche Modular Sys-
tem of <8% for levels between 76 and 925 nmol/l.
The interpretation of the SST is based on the 30 min serum cor-
tisol where an adequate response to Synacthen for Advia Centaur
was defined as >450 nmol/l,27 for Architect as >430 nmol/l 27 and
for the Roche Modular System as >550 nmol/I.27
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Statistical methods
Data presented are expressed as means  standard deviations
(SD) for continuous variables and as counts (%) for categorical
variables. For comparisons of single variables, t-tests were used
while, for analyses involving multiple comparisons, the one-way
ANOVA or, for nonparametric data, the Mann–Whitney test, were
used to determine statistical significance. Frequencies were com-
pared using the chi-squared test.
We performed receiver-operating characteristic (ROC) curves
to evaluate the diagnostic performance of basal cortisol as a pre-
dictor of adrenal sufficiency (AS) analysing sensitivity and speci-
ficity for each possible test threshold/cut-off, and we used the
area under the ROC curve to express the overall diagnostic accu-
racy of the index criterion. In particular, we have reported dif-
ferent thresholds of both specificity and sensitivity: 95%, 99%,
100%. Subsequent to this, separate analyses were performed for
data for different subgroups of cases.
P < 005 was considered indicative of a statistically signif-
icant difference. Statistical analyses were performed using
SPSS (version 17, Chicago, IL, USA) and the GraphPad Prism
60 software package (GraphPad Software, Inc. La Jolla, CA,
USA).
Results
Short synacthen test results
Advia centaur (Siemens) assay. A total of 1019 patients were
included, 416 (408%) males. The mean age was 517  19 years
with an age range of 12–96 years. Overall, 133/1019 patients
(131%) had adrenal insufficiency (AI) as defined by a serum
cortisol <450 nmol/l at 30 min.
Results of the SSTs according to different indications for the
performance of the test are reported in Table 1.
Architect (Abbott) assay. A total of 449 patients were included,
195 (434%) males. The mean (SD) age was 517  183 years
with an age range 18–95 years. Overall, 89/449 patients (198%)
had adrenal insufficiency as defined by a serum cortisol
<430 nmol/l at 30 min.
Results of the SSTs according to different indications for the
performance of the test are reported in Table 1.
Roche modular system (Roche) assay. A total of 2050 patients
were included, 910 (444%) males. The mean (SD) age was
557  192 years with an age range 18–100 years. Overall, 435/
2050 patients (212%) had adrenal insufficiency as determined
by a serum cortisol <550 nmol/l at 30 min.
Results of the SSTs according to different indications for the
performance of the test are reported in Table 1.
Accuracy of baseline morning cortisol in predicting SST
results
We performed ROC curve analyses with the aim of finding a
baseline cortisol level able to predict an accurate value for pass-
ing the SST for each of the three cortisol assays described
(Table 2 and Fig. 1).
Advia centaur (Siemens) assay. Baseline serum cortisol in the
1019 SSTs analysed correlated significantly with the levels
30 min after Synacthen administration (Spearman’s r = 067
P < 0001). A ROC curve performed on this data set showed
that a baseline cortisol ≥358 nmol/l had a specificity of 100%
for predicting passing the SST while a baseline cortisol
Table 1. Results of SST
Indication
Advia Centaur (Siemens) Architect (Abbott) Modular system (Roche)
Total
(n) Pass % (n) Fail % (n)
Total
(n) Pass % (n) Fail % (n)
Total
(n) Pass % (n) Fail % (n)
ALL 1019 869% (886) 131% (133) 449 802% (360) 198% (89) 2050 788% (1615) 212% (435)
Pituitary diseases 390 821% (320) 179% (70) 156 75% (117) 29% (35) 692 796% (551) 204% (141)
Other Tumours of the CNS 119 891% (106) 109% (13) 66 848% (56) 152% (10) 315 749% (236) 251% (79)
Adrenal Disease (Addison’s Disease,
CAH, Adenoma, Carcinoma,
Metastases)
25 60% (15) 40% (10) 26 423% (11) 577% (15) 73 397% (29) 603% (44)
Coexistent Autoimmune Disease
(Type 1 Diabetes Mellitus, Thyroid
Disease, Premature Ovarian Failure,
Vitiligo)
58 966% (56) 34% (2) 13 100% (13) 113 92% (104) 8% (9)
Chronic Steroid Treatment For Disease
Different From Endocrine Conditions
40 30% (12) 70% (28) 32 438% (14) 563% (18) 406 667% (271) 332% (135)
Other (Hyponatraemia, Hyperkalaemia,
Hypoglycaemia, Postural Hypotension,
Syncope, Collapse Or Dizziness,
Weight loss, Nausea, Vomiting,
Diarrhoea or
Abdominal Pain, Fatigue, Malaise)
387 974% (377) 26% (10) 156 955% (149) 45% (7) 451 94% (424) 6% (27)
© 2016 John Wiley & Sons Ltd
Clinical Endocrinology (2016), 0, 1–8
Morning cortisol and HPA reserve in 3 assays 3
≤56 nmol/l had a sensitivity of 100% for predicting failure
(AUC: 0960, 95% CI 0947–0973). Utilizing these criteria,
589 SSTs (578% of all SSTs performed) could have been
avoided.
Architect (Abbott) assay. Baseline serum cortisol in the 449 SSTs
analysed correlated significantly with the levels 30 min after
Synacthen administration (Spearman’s r = 066 P < 0001). A
serum cortisol concentration ≥336 nmol/l provided 100%
specificity for predicting a normal SST response while a baseline
cortisol ≤83 nmol/l gave 100% sensitivity for predicting failure
(AUC: 0872, 95% CI 0831–0913). With these cut-off values,
158 SSTs (352% of all SSTs performed) could have been
avoided.
Roche modular system (Roche) assay. Baseline serum cortisol in
the 2050 SSTs analysed correlated significantly with the levels
30 min after ACTH stimulation (Spearman’s r = 073 P <
0001). A ROC curve performed on this data set showed that a
baseline cortisol ≥506 nmol/l had a specificity of 100% for
predicting a normal SST, and a baseline cortisol ≤102 nmol/l
was 99% sensitive for predicting failure (AUC: 0899, 95% CI
0882–0916). Utilizing these cut-offs, 578 SSTs (282% of all
SSTs performed) could have been avoided.
We then analysed the accuracy of the basal cortisol for each
independent group of pathologies and test indications. The AUC
with 95% CI 0947–0973 and threshold cortisol values for speci-
ficities and sensitivities for each cortisol assay in all patients and
according to different subgroups of indication for the SST are
shown in Table 2, and then analysed according to age, sex,
menopausal status in Supplementary Table 1. Considering the
different indications for the performance of the SST in the three
cortisol assays analysed, there was no clear trend for different
criteria to be used contingent upon a specific pathology except
for the data on patients on GCs treatment in the Roche group,
as previously reported.23
The timing of morning cortisol measurement and its
ability to predict an intact adrenal reserve
To determine whether the timing of the morning cortisol mea-
surement influenced its ability to predict adrenal reserve, we
performed separate analyses of the samples analysed by the
Advia Centaur assay for those tests initiated before or after
1000 h (Table 3).
A total of 443 patients were included in this subgroup analysis
of tests initiated after 1000 h, of whom 197 (445%) were
males. Overall, 37/443 patients (84%) had adrenal insufficiency
as determined by a serum cortisol <450 nmol/l at 30 min. Base-
line serum cortisol in the 443 SSTs analysed correlated signifi-
cantly with the levels 30 min after ACTH stimulation
(Spearman’s r = 066, P < 0001). A ROC curve performed on
this data set showed that a baseline cortisol ≥376 nmol/l had a
specificity of 100% for predicting passing the SST, and a baseline
cortisol ≤35 nmol/l had a sensitivity of 100% for predicting fail-
ure (AUC: 0944, 95% CI 0914–0975).
We calculated positive predictive value (PPV) of baseline
cortisol with given 100% specificity cut-offs for Advia Centaur
performed before and after 1000 h. We calculated a PPV of
277% for baseline cortisol performed before 1000 h and 186%
after 1000 h with Advia Centaur (Siemens).
Age and sex subgroup differentiation
Differentiation of baseline cortisol values according to age and
sex subgroups is shown in Supplementary Table 1. There was no
difference between baseline cortisol in male and female subjects
in the three assays. Patients above 70 years of age showed a sig-
nificantly higher mean baseline cortisol compared to younger
patients both in Advia Centaur (mean cortisol of 3517 in
patients under 70 years vs 4109 nmol/l in patients above
70 years, P =< 0001) and Roche (mean cortisol of 3155 in
patients under 70 years vs 4014 nmol/l in patients above
70 years, P =< 0001) assays, but not in the Architect assay. Fur-
thermore, postmenopausal women had a higher baseline cortisol
compared to premenopausal women in the Advia Centaur
(mean cortisol of 380 vs 347 nmol/l, P = 002) and Roche assays
(mean cortisol of 364 vs 310 nmol/l, P = 0007), but not in the
Architect assay.
Economic aspects
The costs for Synacthen have varied over time, and in the UK,
this cost has recently increased substantially: currently, the price
to the National Health Service for a single Synacthen ampoule is
£4571, with additional costs for nursing and medical supervi-
sion (varying with level of experience).
In the three populations analysed, we calculated that the num-
ber of SSTs that could have been saved according to the given
specificity and sensitivity baseline cortisol thresholds would have
been 589 for Advia Centaur (Siemens), 158 for Architect (Abbott)
and 578 for the Roche Modular system (Roche). Given these
numbers, performing the basal cortisol and using the proposed
cut-offs could lead to a significant cost saving.
Discussion
In the present study, we have confirmed that there is a strong
correlation between basal morning cortisol and the response to
Synacthen administration, as previously described.8,23,26 For the
first time, we have evaluated three commonly employed cortisol
assays and large patient database and we suggest basal levels of
serum cortisol which strongly predict a normal response to Syn-
acthen and thus could be used to avoid unnecessary dynamic
testing. Our results also confirm the variability in cortisol assess-
ment dependent on the assay used,23 and thus, the inherent
inaccuracy in specifying normative data on cortisol levels with-
out specify the assay used.
Previous studies have shown that a basal cortisol of
<100 nmol/l is highly predictive of adrenal insufficiency (AI)
22,26,29,30 but there is no consensus in the literature as to a level
of basal morning cortisol that can accurately predict adrenal
© 2016 John Wiley & Sons Ltd
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sufficiency,20,22,30,31 at least in part due to the use of different
cortisol assays.
Interestingly, a previous study 23 showed that baseline morn-
ing cortisol levels that predict the outcome of SST are signifi-
cantly lower in patients exposed to glucocorticoid (GC) therapy
(baseline cortisol of 410 nmol/l showed 100% specificity for pre-
dicting passing the SST and a serum cortisol concentration of
34 nmol/l had 100% sensitivity for predicting failure) and even
more in the subgroup of patients taking inhaled GCs (baseline
morning cortisol of 348 nmol/l gave 100% specificity for pre-
dicting passing the SST and of 34 nmol/l showed 100% sensitiv-
ity for predicting failure) compared to all patients that had SST
performed for all indications (serum cortisol concentration of
506 nmol/l was 100% specific for predicting passing the SST
and of 107 nmol/l was 99% sensitive for predicting failure).
Our results confirm previous data concerning the usefulness
of morning cortisol level in the assessment of adrenal reserve,23
but this is the first study that analysed morning cortisol level of
three commonly used cortisol assay to predict SST outcome. We
recommend that to assess the HPA axis one should perform a
morning basal cortisol as the first diagnostic test when suspect-
ing adrenal insufficiency. Considering that AI is a condition with
serious consequences if undiagnosed, we have investigated the
basal cortisol with a 100% specificity in excluding failure to the
SST and hence AI. Thus, a morning basal cortisol level
≥358 nmol/l for Advia Centaur (Siemens), ≥336 nmol/l for
Architect (Abbott) and ≥506 nmol/l for the Roche Modular Sys-
tem (Roche), the last one as previously reported,23 was highly
predictive of adrenal sufficiency in this cohort of more than
3000 SSTs. These criteria appeared to be independent of disease
or indication for the SST, except for the data on patients on GC
treatment in the Roche assay as previously reported.23 However,
it should be noted that the Advia Centaur assay has undergone
several ‘realignments’, although it is unclear as to whether this
has affected its threshold levels. In addition, the Roche assay has
been replaced by Roche II, for which preliminary data show
broad alignment with the Architect assay and thus a normative
threshold in the region of 420–430 nmol/l.
Overall, using a baseline morning cortisol as the first step and
utilizing the proposed cut-offs, 29% of SST could have been
avoided leading to a significant decrease of unnecessary tests for
patients, work and efforts for nursing and medical staff and
relevant cost savings.
Limitations
The principal limitations of this study are the retrospective nat-
ure of data collection and the institutional referral bias that may
lead to a potential positive selection bias that may overestimate
the prevalence rate of severe conditions and the percentage of
patient failing the SST. Furthermore, a substantial number of
the patients from Birmingham, using the Roche assay, underwent
the SST after 1000 h. It should be noted, however, that the nor-
mative values for the SST are independent of the time of day.
However, even though most patients will be diagnosed with
high accuracy using these morning baseline cortisol criteria, clini-
cal judgement is essential in deciding when to totally rely on such
values. Furthermore, while the SST is extremely useful in defining
an adequate reserve of the HPA axis in most situations, there may
still be situations where a complete test of the HPA axis is neces-
sary, and then, the ITT or related investigation should be used. It
may also be noted that while the SST closely correlates with the
ITT, the latter essentially tests the whole HPA axis and thus repre-
sents a more appropriate biological response.32
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Fig. 1 Baseline serum cortisol as a predictor of SST outcome in three cortisol immunoassay. Baseline serum cortisol is graphed against the %
likelihood of passing (specificity: continuous line) or failing (sensitivity: dashed line) the SST.
Table 3. Comparison between before 1000 h and after 1000 h cortisol
in terms of results of SST, accuracy of baseline cortisol in predicting
SST’s results, false positive (FP) and PPV (positive predicting value)
Before 1000 h After 1000 h
n 1019 443
Pass % (n) 869% (886) 916% (406)
Fail % (n) 131% (133) 84% (37)
AUC (95% CI) 0960 (0947–0973) 0944 (0914–0975)
Specificity 95% 277 nmol/l 314 nmol/l
Specificity 99% 344 nmol/l –
Specificity 100% 358 nmol/l 376 nmol/l
Sensitivity 95% 1845 nmol/l 151 nmol/l
Sensitivity 99% 123 nmol/l 62 nmol/l
Sensitivity 100% 56 nmol/l 35 nmol/l
FP (n) 346 162
PPV (%) 277 186
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In conclusion, the morning basal cortisol is an easy to per-
form, cheap and safe test and represents a valid tool for the ini-
tial assessment of adrenal function and of HPA axis integrity. It
reduces the use of unnecessary dynamic function tests with an
associated reduction in cost and risks of adverse reactions for
patient. Thus, we recommend the use of the morning baseline
cortisol as the first test in the evaluation of patients with sus-
pected adrenal insufficiency, and we provide normative values
from a large cohort of patients evaluating three commonly used
cortisol assays to minimize the use of the SST and save time and
resources.
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